MY142746A - Heterocyclic compound - Google Patents

Heterocyclic compound

Info

Publication number
MY142746A
MY142746A MYPI20061668A MYPI20061668A MY142746A MY 142746 A MY142746 A MY 142746A MY PI20061668 A MYPI20061668 A MY PI20061668A MY PI20061668 A MYPI20061668 A MY PI20061668A MY 142746 A MY142746 A MY 142746A
Authority
MY
Malaysia
Prior art keywords
group
heterocyclic compound
alkylene group
ring
present
Prior art date
Application number
MYPI20061668A
Inventor
Hiroshi Yamashita
Jun Shimada
Kenji Maeda
Yoshihiro Tadori
Naoki Amada
Hitomi Akazawa
Junko Yamashita
Atsushi Mori
Yasufumi Uwahodo
Takumi Masumoto
Tetsuro Kikuchi
Jun Matsubara
Kazuya Hashimoto
Haruka Takahashi
Kunio Oshima
Hideaki Kuroda
Nobuaki Ito
Shin Miyamura
Satoshi Shimizu
Tatsuyoshi Tanaka
Yasuo Oshiro
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645750&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY142746(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MY142746A publication Critical patent/MY142746A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

THE PRESENT INVENTION PROVIDES A HETEROCYCLIC COMPOUND REPRESENTED BY THE GENERAL FORMULA (1): 5 R2 /-I-\ A-N N (1) WHEREIN RING Q REPRESENTED BY REPRESENTS @Y Z (WHEREIN-ZY- REPRESENTS -NH-CH2-, -N=CH-, -CH2-NH- OR -CH=N-) ;THE RING Q MAY HAVE AT LEAST ONE SUBSTITUENT SELECTED FROM THE GROUP CONSISTING OF A LOWER ALKYL GROUP, A LOWER ALKENYL GROUP, ETC.; R2 REPRESENTS A HYDROGEN ATOM OR A LOWER ALKYL GROUP; AND A REPRESENTS –O-A1- (WHEREIN A1 REPRESENTS AN ALKYLENE GROUP WHICH MAY BE SUBSTITUTED WITH A HYDROXY GROUP (WHEREIN THE ALKYLENE GROUP MAY CONTAIN ONE OXYGEN ATOM) OR A LOWER ALKENYLENE GROUP) OR A LOWER ALKYLENE GROUP )OR A SALT THEREOF.THE COMPOUND OF THE PRESENT INVENTION HAS A WIDE TREATMENT SPECTRUM FOR MENTAL DISORDERS INCLUDING CENTRAL NERVOUS SYSTEM DISORDERS , NO SIDE EFFECTS AND HIGH SAFETY.
MYPI20061668A 2005-04-14 2006-04-12 Heterocyclic compound MY142746A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005116698 2005-04-14

Publications (1)

Publication Number Publication Date
MY142746A true MY142746A (en) 2010-12-31

Family

ID=36645750

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20061668A MY142746A (en) 2005-04-14 2006-04-12 Heterocyclic compound

Country Status (27)

Country Link
US (14) USRE48059E1 (en)
EP (1) EP1869025B3 (en)
KR (1) KR100937623B1 (en)
CN (1) CN101155804B (en)
AR (1) AR053577A1 (en)
AT (1) ATE496911T3 (en)
AU (1) AU2006237905C1 (en)
BR (1) BRPI0609785B8 (en)
CA (1) CA2602247C (en)
CY (2) CY1111206T1 (en)
DE (1) DE602006019838D1 (en)
DK (1) DK1869025T6 (en)
ES (1) ES2358631T7 (en)
HK (1) HK1112236A1 (en)
HU (2) HUE011611T6 (en)
IL (1) IL185909A (en)
IN (1) IN2012DN00855A (en)
LT (1) LTC1869025I2 (en)
LU (1) LUC00086I2 (en)
MY (1) MY142746A (en)
NL (1) NL300946I2 (en)
PL (1) PL1869025T6 (en)
PT (1) PT1869025E (en)
SI (1) SI1869025T1 (en)
TW (1) TWI320783B (en)
WO (1) WO2006112464A1 (en)
ZA (1) ZA200708686B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012254A1 (en) 2003-07-22 2005-02-10 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
SA05260357B1 (en) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2007136680A2 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2536762T3 (en) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Primary amines and their derivatives as 5-HT2A serotonin receptor modulators useful for the treatment of disorders related to this
MX349156B (en) 2006-05-18 2017-07-14 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor.
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
AR063302A1 (en) * 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd DERIVATIVES OF 4-BENZO [B] TIOFEN-4-IL-PIPERAZIN-1-IL WITH ANTAGONIST ACTION OF THE 5-HT2A SEROTONINE RECEIVER AND ADRENALINE ALFA1 RECEPTOR AND PARTIAL AGRONIST OF THE D2 RECEPTOR, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND UNDERSTANDS TO PRODUCE IT.
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN101952278A (en) * 2008-02-15 2011-01-19 弗·哈夫曼-拉罗切有限公司 3-alkyl-piperazine derivatives and uses thereof
US8349826B2 (en) 2008-02-22 2013-01-08 Actelion Pharmaceuticals Ltd. Oxazolidinone derivatives
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
SI2364142T1 (en) 2008-10-28 2018-06-29 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
HRP20171415T4 (en) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2834973T3 (en) 2010-05-04 2021-06-21 Alkermes Pharma Ireland Ltd Process for the synthesis of oxidized lactam compounds
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JOP20120083B1 (en) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
EP2736894B1 (en) * 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b] thiophene compounds
JO3227B1 (en) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd Piperazine-substituted benzothiophene deriveatives as antipsychotic agents
JO3753B1 (en) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
TWI679977B (en) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 Solution for oral administration
TW201332572A (en) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd Pharmaceutical preparation comprising substituted β -cyclodextrin
JOP20200109A1 (en) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd Injectable preparation
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (en) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd INJECTABLE PREPARATION
US9951088B2 (en) * 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
JOP20210047A1 (en) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
EP2792359A1 (en) * 2013-04-19 2014-10-22 Merz Pharma GmbH & Co. KGaA Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712
KR101472916B1 (en) * 2013-06-27 2014-12-16 한국과학기술연구원 Pharmaceutical composition comprising morpholine or piperazine based compounds, and donepezil for preventing or treating cognitive impairment-related disease
CN104557896A (en) 2013-10-18 2015-04-29 沈敬山 Brexpiprezole, and preparation methods of key intermediate and salt thereof
CN104892589A (en) 2014-03-07 2015-09-09 中国科学院上海药物研究所 Heterocyclic compound, preparation method therefor and use thereof
MX2016013889A (en) * 2014-04-22 2017-03-09 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders.
CN104447723A (en) * 2014-11-28 2015-03-25 瑞阳制药有限公司 Method for preparing 7-(4-(4-(benzo[b]thienyl)-1-piperazinyl) butoxy)-2(1H)-quinolinone
CN105461703B (en) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 A kind of preparation method of brexpiprazole
CN105985314A (en) * 2015-02-05 2016-10-05 苏州旺山旺水生物医药有限公司 Preparation method of brexpiprazole analogue
CN104844586A (en) * 2015-04-16 2015-08-19 重庆医药工业研究院有限责任公司 Amorphous brexpiprazole and preparation method thereof
CN104829588B (en) * 2015-04-30 2017-03-29 苏州苏旺森生物医药科技有限公司 A kind of Preparation Method And Their Intermediate of benzo [b] thiophene
CN104829603A (en) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 Crystal form A brexpiprazole hydrochloride and preparation method thereof
MX2017016413A (en) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder.
MX2018000465A (en) 2015-07-15 2018-09-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease.
CN105061414B (en) * 2015-07-21 2019-01-01 杭州新博思生物医药有限公司 One kettle way prepares Brexpiprazole
WO2017025987A1 (en) 2015-08-11 2017-02-16 Mylan Laboratories Limited Process for the preparation of brexpiprazole
EP3150591A1 (en) 2015-10-02 2017-04-05 Crystal Pharma S.A.U Process and intermediates for the preparation of benzo[b]thiophene compounds
CN106749219A (en) 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 A kind of lactam derivative and its application
CN105440026A (en) * 2015-12-04 2016-03-30 上海勋和医药科技有限公司 Elopiprazole preparation method
CN105461704A (en) * 2015-12-15 2016-04-06 南京艾德凯腾生物医药有限责任公司 Preparing method for brexpiprazole
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
CN106916148B (en) * 2015-12-25 2021-07-06 上海科胜药物研发有限公司 Method for synthesizing brexpiprazole
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
CN106938982A (en) * 2016-01-05 2017-07-11 连云港皓海医药科技有限公司 The preparation method of the auspicious piperazine azoles of cloth and the compound for preparing the auspicious piperazine azoles of cloth
CN105399736B (en) * 2016-01-07 2018-10-19 安徽省逸欣铭医药科技有限公司 It is a kind of according to the new preparation method of piperazine azoles
WO2017134038A1 (en) 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
CN105541819B (en) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 A kind of preparation method of the Preparation Method And Their Intermediate and intermediate of epirizole group
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (en) 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 One kind is according to piperazine azoles novel crystal forms and preparation method thereof
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2017216661A1 (en) 2016-06-17 2017-12-21 Jubilant Generics Limited Process for the preparation of brexpiprazole from 7-(4-chlorobutoxy)quinolin-2(1h)-one and 1-(benzo[b]thiophen-4-yl)piperazine
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PL233778B1 (en) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Method for producing brexpiprazole, intermediate compounds used in this method and method for producing them
WO2018033484A1 (en) 2016-08-16 2018-02-22 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
EP3500247B1 (en) 2016-08-16 2020-05-27 H e x a l Aktiengesellschaft Immediate release tablet of a benzothiophene compound
WO2018060916A1 (en) * 2016-09-28 2018-04-05 Alembic Pharmaceuticals Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107936005A (en) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 One kind is according to piperazine azoles novel crystal forms II and preparation method thereof
WO2018087775A1 (en) * 2016-11-09 2018-05-17 Msn Laboratories Private Limited, R&D Center Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1h)-one
CN111233848A (en) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 Epipprazole methanol compound, crystal form A, preparation method and application thereof
US11072605B2 (en) 2017-02-02 2021-07-27 Hexal Ag Crystalline brexpiprazole
WO2018172463A1 (en) 2017-03-22 2018-09-27 Amneal Pharmaceuticals Company Gmbh Process for the preparation of brexpiprazole
WO2019073481A1 (en) * 2017-10-12 2019-04-18 Indoco Remedies Limited Process for the preparation of brexpiprazole and its intermediates
AR113926A1 (en) 2017-12-14 2020-07-01 H Lundbeck As DERIVATIVES OF 1H-PYRAZOLE [4,3-B] PYRIDINES
JP7261801B2 (en) 2017-12-14 2023-04-20 ハー・ルンドベック・アクチエゼルスカベット Combination therapy including administration of 1H-pyrazolo[4,3-B]pyridine
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN111511742B (en) 2017-12-20 2023-10-27 H.隆德贝克有限公司 Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors
CN109988162A (en) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 One kind is according to piperazine Zole derivatives and preparation method thereof
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
WO2019242717A1 (en) * 2018-06-21 2019-12-26 中国科学院上海药物研究所 Maleate salt of benzothiophene compound, crystalline form thereof, and use thereof
CN108947990A (en) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 A kind of preparation method of benzothiophenes
CN111320582A (en) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 Preparation method of amide-like derivative and intermediate thereof
CN111320619A (en) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 Impurities of amide-like derivatives and application
CN109970705B (en) * 2019-05-14 2021-02-09 浙江工业大学 Method for preparing brexpiprazole intermediate and brexpiprazole by using cheap metal copper
JPWO2021029020A1 (en) * 2019-08-13 2021-02-18
WO2021207532A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CN116096715A (en) * 2020-07-06 2023-05-09 泰科根公司 Beneficial benzothiophene compositions for mental disorders or enhancement
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN114181202A (en) * 2021-12-17 2022-03-15 湖南省湘中制药有限公司 Preparation method of brexpiprazole

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910955A (en) 1970-12-21 1975-10-07 Aspro Nicholas Ltd Benzothiophene-ethylamines
DK574274A (en) 1973-12-06 1975-07-28 Ciba Geigy Ag
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (en) 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2827566A1 (en) 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-DIHYDRO-CHINOLIN-2-ON DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS56164186A (en) 1980-05-21 1981-12-17 Otsuka Pharmaceut Co Ltd Carbostyril derivative
IT1201087B (en) 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
ATE81975T1 (en) 1984-12-21 1992-11-15 Duphar Int Res MEDICATIONS WITH PSYCHOTROPIC EFFECTS.
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
GB8704572D0 (en) 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5436246A (en) 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
DK148392D0 (en) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocyclic Compounds
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
CN1154105A (en) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines, tetrahydropyridines or piperazines
CA2157348A1 (en) 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0732332B1 (en) * 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
CR5278A (en) 1995-03-24 1996-07-04 Lilly Co Eli ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE
FR2735127B1 (en) 1995-06-09 1997-08-22 Pf Medicament NEW HETEROAROMATIC PIPERAZINES USEFUL AS MEDICAMENTS.
ATE187172T1 (en) 1995-09-15 1999-12-15 Sanofi Synthelabo QUINOLIN-2-ONE DERIVATIVES AS SEROTONIN ANTAGONISTS
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
DE69736704T2 (en) 1996-03-29 2007-09-13 Duphar International Research B.V. PIPERAZIN AND PIPERIDINE DERIVATIVES
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP0934932A4 (en) 1996-08-22 2002-06-26 Meiji Seika Kaisha Quinoline derivatives and psychotropic agent
FR2761068B1 (en) 1997-03-20 1999-04-23 Synthelabo PIPERAZIN-4-YLTHIENO [3,2-C] PYRIDIN-4-YL-2- CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ES2128266B1 (en) 1997-07-08 2000-01-16 Vita Invest Sa THIOPHENE AND BENZOTIOFEN DERIVATIVE COMPOUNDS AND RELEVANT USE AND COMPOSITION.
DE69819266T2 (en) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidine and piperazine derivatives as 5-HT1 receptor agonists
EP0901787B1 (en) 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
EP0982304B1 (en) 1998-06-30 2002-10-02 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
AR022303A1 (en) 1999-01-22 2002-09-04 Lundbeck & Co As H DERIVATIVES OF PIPERIDINE, TETRAHYDROPIRIDINE AND PIPERAZINE, ITS PREPARATION AND USE
CA2716369C (en) 1999-05-24 2013-05-14 Mitsubishi Tanabe Pharma Corporation Phenoxypropylamine compounds
EP1204660B1 (en) 1999-07-29 2004-10-20 Eli Lilly And Company Serotonergic benzothiophenes
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
WO2001046179A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
AR027133A1 (en) 1999-12-30 2003-03-12 Lundbeck & Co As H DERIVATIVES OF HETEROARILO, ITS PREPARATION AND USE.
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
DE10043659A1 (en) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2188344B1 (en) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. COMPOUNDS DERIVED FROM BENZOTIOPHENE, ITS PROCEDURE FOR OBTAINING AND USING THEMSELVES.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
JP4497815B2 (en) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
JP4310605B2 (en) 2001-05-25 2009-08-12 大塚製薬株式会社 Pharmaceutical composition
AR033485A1 (en) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
DE10151569A1 (en) 2001-10-23 2003-04-30 Basf Ag Thermally curable binders
US20030153617A1 (en) 2001-12-18 2003-08-14 Dalen Frans Van Simvastatin dosage forms
WO2004026864A1 (en) 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
KR20050057448A (en) 2002-09-20 2005-06-16 오스람 옵토 세미컨덕터스 게엠베하 Optical scanning head and method for producing the same
WO2004029048A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
CA2458929C (en) 2003-01-09 2009-09-08 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
EP2601953A1 (en) 2003-05-23 2013-06-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
GB0504203D0 (en) 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP1858514B1 (en) 2005-03-17 2014-11-26 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
UA97349C2 (en) 2005-09-08 2012-02-10 Х. Луннбэк А/С Stable solid formulation of sertindole
PL1808164T3 (en) 2006-01-05 2009-06-30 Teva Pharma Wet granulation method for preparing pharmaceutical compositions of aripiprazole
CN101678006A (en) 2007-05-11 2010-03-24 参天制药株式会社 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US7968431B2 (en) 2008-07-15 2011-06-28 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
WO2010052727A1 (en) 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
EP2736894B1 (en) * 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b] thiophene compounds
JO3227B1 (en) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd Piperazine-substituted benzothiophene deriveatives as antipsychotic agents
JO3753B1 (en) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
ATE496911T3 (en) 2011-02-15
IL185909A0 (en) 2008-01-06
DK1869025T3 (en) 2011-04-04
EP1869025A1 (en) 2007-12-26
DK1869025T6 (en) 2017-01-02
US8349840B2 (en) 2013-01-08
TW200716619A (en) 2007-05-01
PT1869025E (en) 2011-02-04
BRPI0609785A2 (en) 2010-04-27
ZA200708686B (en) 2009-01-28
KR20080002817A (en) 2008-01-04
PL1869025T3 (en) 2011-06-30
AU2006237905C1 (en) 2015-11-19
US20190117648A1 (en) 2019-04-25
US9839637B1 (en) 2017-12-12
US20170368060A1 (en) 2017-12-28
AR053577A1 (en) 2007-05-09
HUE011611T6 (en) 2017-04-28
PL1869025T6 (en) 2017-10-31
SI1869025T1 (en) 2011-04-29
CY2018028I2 (en) 2019-07-10
CN101155804B (en) 2013-03-27
US20190321359A1 (en) 2019-10-24
KR100937623B1 (en) 2010-01-20
NL300946I2 (en) 2018-09-26
IN2012DN00855A (en) 2015-07-10
US20170000786A1 (en) 2017-01-05
CN101155804A (en) 2008-04-02
HK1112236A1 (en) 2008-08-29
US7888362B2 (en) 2011-02-15
US20160051548A1 (en) 2016-02-25
USRE48059E1 (en) 2020-06-23
US20180214444A1 (en) 2018-08-02
CA2602247C (en) 2013-04-02
US20100179322A1 (en) 2010-07-15
US9206167B2 (en) 2015-12-08
LTPA2018509I1 (en) 2018-09-10
CY1111206T1 (en) 2015-06-11
IL185909A (en) 2014-08-31
DE602006019838D1 (en) 2011-03-10
BRPI0609785B1 (en) 2020-10-20
EP1869025B1 (en) 2011-01-26
US20200237755A1 (en) 2020-07-30
LUC00086I2 (en) 2018-11-26
HUS1800041I1 (en) 2018-11-28
CY2018028I1 (en) 2019-07-10
AU2006237905B2 (en) 2009-09-03
US9480686B2 (en) 2016-11-01
ES2358631T7 (en) 2016-11-17
ES2358631T3 (en) 2011-05-12
WO2006112464A1 (en) 2006-10-26
US20140163039A1 (en) 2014-06-12
EP1869025B3 (en) 2016-08-31
US20210113556A1 (en) 2021-04-22
US20170231983A1 (en) 2017-08-17
US20110152286A1 (en) 2011-06-23
BRPI0609785B8 (en) 2021-05-25
LTC1869025I2 (en) 2019-05-10
AU2006237905A1 (en) 2006-10-26
US20130158044A1 (en) 2013-06-20
TWI320783B (en) 2010-02-21
US8618109B2 (en) 2013-12-31
CA2602247A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
MY142746A (en) Heterocyclic compound
MY145670A (en) Heterocyclic compound
WO2009016462A3 (en) Substituted bicyclolactam compounds
HK1107227A1 (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
MX2009003821A (en) N-aryl pyrazole compounds for use against diabetes.
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
MX2009007075A (en) Methods of use for cyclopamine analogs.
MX2008012399A (en) Ceramide kinase modulation.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TW200635509A (en) 5-Alkoxyalkyl-6-alkyl-7-aminoazolopyrimidines, process for their preparation, their use for controlling harmful fungi, and compositions comprising them
MX2011008305A (en) Pyridazinone compounds.
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP1717238A4 (en) Fungicidal heterocyclic compounds
UA96568C2 (en) Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
MX2010005649A (en) Novel compounds as cannabinoid receptor ligands and uses thereof.
WO2009057784A1 (en) Heterocyclic compound
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
NO20082630L (en) Water-soluble benzoazepine compounds and pharmaceutical compound
MX2009011076A (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient.
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MY164789A (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine
WO2008036196A3 (en) Indolylalkylpyridin-2-amines for the inhibition of beta-secretase
MY140963A (en) Phenylpyridylpiperazine compounds
WO2006133339A3 (en) Monoamine re-uptake inhibitors and methods relating thereto
WO2008063548A3 (en) 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents